Niagen Bioscience Statistics
Niagen Bioscience (OCD1) Stock Statistics & Valuation Metrics
Total Valuation
Niagen Bioscience has a market cap or net worth of EUR 148.36M. The enterprise value is EUR 163.68M.
- Market Cap
- EUR 148.36M
- Enterprise Value
- EUR 163.68M
Share Statistics
Niagen Bioscience has 79,196,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 79,196,900
- Owned by Insiders
- 5.07%
- Owned by Institutions
- 29.63%
Financial Efficiency
Niagen Bioscience’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 15.61%.
- Return on Equity (ROE)
- 0.23
- Return on Assets (ROA)
- 0.16
- Return on Invested Capital (ROIC)
- 15.61%
- Return on Capital Employed (ROCE)
- 0.17
- Revenue Per Employee
- 1.11M
- Profits Per Employee
- 148.56K
- Employee Count
- 117
- Asset Turnover
- 1.22
- Inventory Turnover
- 2.26
Valuation Ratios
The current PE Ratio of Niagen Bioscience is 16.31. Niagen Bioscience’s PEG ratio is -0.33.
- PE Ratio
- 16.31
- PS Ratio
- 1.34
- PB Ratio
- 1.97
- Price to FCF
- 35.72
- Price to Operating Cash Flow
- 33.48
- PEG Ratio
- -0.33
Income Statement
In the last 12 months, Niagen Bioscience had revenue of 129.42M and earned 17.38M in profits. Earnings per share was 0.22.
- Revenue
- 129.42M
- Gross Profit
- 83.19M
- Operating Income
- 14.30M
- Pretax Income
- 18.19M
- Net Income
- 17.38M
- EBITDA
- 19.64M
- Earnings Per Share (EPS)
- 0.22
Cash Flow
In the last 12 months, operating cash flow was 4.88M and capital expenditures -303,000, giving a free cash flow of 4.58M billion.
- Operating Cash Flow
- 4.88M
- Free Cash Flow
- 4.58M
- Free Cash Flow per Share
- 0.06
Dividends & Yields
Niagen Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.80%
- Earnings Yield
- 6.27%
Stock Price Statistics
- Beta
- 1.07
- 52-Week Price Change
- -67.76%
- 50-Day Moving Average
- 2.19
- 200-Day Moving Average
- 2.97
- Relative Strength Index (RSI)
- 46.53
- Average Volume (3m)
- ―
Important Dates
Niagen Bioscience upcoming earnings date is Mar 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Niagen Bioscience as a current ratio of 4.86, with Debt / Equity ratio of 3.68%
- Current Ratio
- 4.86
- Quick Ratio
- 3.83
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -3.16
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Niagen Bioscience has paid 810.00K in taxes.
- Income Tax
- 810.00K
- Effective Tax Rate
- 0.04
Enterprise Valuation
Niagen Bioscience EV to EBITDA ratio is 13.75, with an EV/FCF ratio of 36.17.
- EV to Sales
- 1.35
- EV to EBITDA
- 13.75
- EV to Free Cash Flow
- 36.17
- EV to Operating Cash Flow
- 33.92
Balance Sheet
Niagen Bioscience has EUR 0.00 in cash and marketable securities with EUR 2.08M in debt, giving a net cash position of -EUR 2.08M billion.
- Cash & Marketable Securities
- EUR 0.00
- Total Debt
- EUR 2.08M
- Net Cash
- -EUR 2.08M
- Net Cash Per Share
- -EUR 0.03
- Tangible Book Value Per Share
- EUR 0.98
Margins
Gross margin is 63.86%, with operating margin of 2.28%, and net profit margin of 8.37%.
- Gross Margin
- 63.86%
- Operating Margin
- 2.28%
- Pretax Margin
- 9.04%
- Net Profit Margin
- 8.37%
- EBITDA Margin
- 9.85%
- EBIT Margin
- 8.40%
Analyst Forecast
The average price target for Niagen Bioscience is EUR 7.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 7.40
- Price Target Upside
- 295.62% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- -6.71%
- EPS Growth Forecast
- -53.86%
Scores
- Smart Score
- 3
- AI Score
- ―

